These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 32346837)

  • 1. Systemic treatment of breast cancer with leptomeningeal metastases using bevacizumab, etoposide and cisplatin (BEEP regimen) significantly improves overall survival.
    Chen TW; Jan IS; Chang DY; Lin CH; Chen IC; Chen HM; Cheng AL; Lu YS
    J Neurooncol; 2020 May; 148(1):165-172. PubMed ID: 32346837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole-Brain Radiotherapy Alone vs Preceded by Bevacizumab, Etoposide, and Cisplatin for Untreated Brain Metastases From Breast Cancer: A Randomized Clinical Trial.
    Chen TW; Dai MS; Tseng LM; Chen SC; Chao TY; Chao TC; Chang YC; Chiu CF; Liu CT; Lin CH; Liu CY; Chen YF; Chang DY; Yu JC; Rau KM; Hsieh YY; Shen SC; Huang SM; Cheng AL; Lu YS
    JAMA Oncol; 2024 Mar; 10(3):325-334. PubMed ID: 38127335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Durable Response of Leptomeningeal Metastasis of Breast Cancer to Salvage Intrathecal Etoposide After Methotrexate: A Case Report and Literature Review.
    Park MJ
    Am J Case Rep; 2015 Aug; 16():524-7. PubMed ID: 26258900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast cancer leptomeningeal metastasis: the results of combined treatment and the comparison of methotrexate and liposomal cytarabine as intra-cerebrospinal fluid chemotherapy.
    Niwińska A; Rudnicka H; Murawska M
    Clin Breast Cancer; 2015 Feb; 15(1):66-72. PubMed ID: 25287959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: A prospective and single-arm study.
    Pan Z; Yang G; He H; Zhao G; Yuan T; Li Y; Shi W; Gao P; Dong L; Li Y
    Int J Cancer; 2016 Oct; 139(8):1864-72. PubMed ID: 27243238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report.
    Stemmler HJ; Mengele K; Schmitt M; Harbeck N; Laessig D; Herrmann KA; Schaffer P; Heinemann V
    Anticancer Drugs; 2008 Sep; 19(8):832-6. PubMed ID: 18690096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab preconditioning followed by Etoposide and Cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy.
    Lu YS; Chen TW; Lin CH; Yeh DC; Tseng LM; Wu PF; Rau KM; Chen BB; Chao TC; Huang SM; Huang CS; Shih TT; Cheng AL;
    Clin Cancer Res; 2015 Apr; 21(8):1851-8. PubMed ID: 25700303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer leptomeningeal metastasis--the role of multimodality treatment.
    Rudnicka H; Niwińska A; Murawska M
    J Neurooncol; 2007 Aug; 84(1):57-62. PubMed ID: 17310266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis.
    Wu PF; Lin CH; Kuo CH; Chen WW; Yeh DC; Liao HW; Huang SM; Cheng AL; Lu YS
    BMC Cancer; 2015 Apr; 15():299. PubMed ID: 25928457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab might potentiate the chemotherapeutic effect in breast cancer patients with leptomeningeal carcinomatosis.
    Chen IC; Lin CH; Jan IS; Cheng AL; Lu YS
    J Formos Med Assoc; 2016 Apr; 115(4):243-8. PubMed ID: 25890495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical features and outcome of leptomeningeal metastasis in patients with breast cancer: a single center experience.
    Jo JC; Kang MJ; Kim JE; Ahn JH; Jung KH; Gong G; Kim HH; Ahn SD; Kim SS; Son BH; Ahn SH; Kim SB
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):201-7. PubMed ID: 23670641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer.
    Stemmler HJ; Schmitt M; Harbeck N; Willems A; Bernhard H; Lässig D; Schoenberg S; Heinemann V
    Oncol Rep; 2006 May; 15(5):1373-7. PubMed ID: 16596213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leptomeningeal Metastasis in a Breast Cancer Treated with Two Lines of Intrathecal Chemotherapy - a Case Report.
    Mikudova V; Rejlekova K; Gyarfas J; Oravcova I; Chovanec M; Mardiak J; Mego M
    Klin Onkol; 2019; 32(2):139-142. PubMed ID: 30995855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen.
    Fizazi K; Asselain B; Vincent-Salomon A; Jouve M; Dieras V; Palangie T; Beuzeboc P; Dorval T; Pouillart P
    Cancer; 1996 Apr; 77(7):1315-23. PubMed ID: 8608509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrathecal trastuzumab in the management of HER2+ breast leptomeningeal disease: a single institution experience.
    Figura NB; Long W; Yu M; Robinson TJ; Mokhtari S; Etame AB; Tran ND; Diaz R; Soliman H; Han HS; Sahebjam S; Forsyth PA; Ahmed KA
    Breast Cancer Res Treat; 2018 Jun; 169(2):391-396. PubMed ID: 29392582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes of breast leptomeningeal disease treated with intrathecal trastuzumab, intrathecal chemotherapy, or whole brain radiation therapy.
    Figura NB; Rizk VT; Mohammadi H; Evernden B; Mokhtari S; Yu HM; Robinson TJ; Etame AB; Tran ND; Liu J; Washington I; Diaz R; Czerniecki BJ; Soliman H; Han HS; Sahebjam S; Forsyth PA; Ahmed KA
    Breast Cancer Res Treat; 2019 Jun; 175(3):781-788. PubMed ID: 30859348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrathecal chemotherapy combined with systemic therapy in patients with refractory leptomeningeal metastasis of non-small cell lung cancer: a retrospective study.
    Zhou T; Zhu S; Xiong Q; Gan J; Wei J; Cai J; Liu A
    BMC Cancer; 2023 Apr; 23(1):333. PubMed ID: 37041504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sanctuary site leptomeningeal metastases in HER-2 positive breast cancer: A review in the era of trastuzumab.
    Kordbacheh T; Law WY; Smith IE
    Breast; 2016 Apr; 26():54-8. PubMed ID: 27017242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of intrathecal administration of trastuzumab in patients with HER2-positive breast cancer with leptomeningeal metastasis.
    Oberkampf F; Gutierrez M; Trabelsi Grati O; Le Rhun É; Trédan O; Turbiez I; Kadi A; Dubot C; Taillibert S; Vacher S; Bonneau C
    Neuro Oncol; 2023 Feb; 25(2):365-374. PubMed ID: 35868630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors and clinical outcomes in patients with leptomeningeal metastasis from solid tumors.
    Waki F; Ando M; Takashima A; Yonemori K; Nokihara H; Miyake M; Tateishi U; Tsuta K; Shimada Y; Fujiwara Y; Tamura T
    J Neurooncol; 2009 Jun; 93(2):205-12. PubMed ID: 19043775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.